试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-01
Intravenous Ketamine Effects on Functional Neuroanatomy
编号:NCT04205890登记状态:入组前撤回企业 / 申办者:Neurological Associates of West Los Angeles
药物 / 成分:Ketamine
登记的停止原因(原文):Sponsor is no longer interested in funding the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-01
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
编号:NCT04332549登记状态:入组前撤回企业 / 申办者:Sun Pharma Advanced Research Company Limited
药物 / 成分:PICS (Reconstitution Method 1 or 2)
登记的停止原因(原文):After meeting with the FDA, SPARC concludes a BE study will not be required
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-29
Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease
编号:NCT03335020登记状态:入组前撤回企业 / 申办者:Mayo Clinic
药物 / 成分:Shear Wave Elastography、Pulse Wave Imaging、Contrast-Enhanced Ultrasound、Strain Imaging
登记的停止原因(原文):Closed by Investigator
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-29
Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome
编号:NCT03457025登记状态:入组前撤回企业 / 申办者:NYU Langone Health
药物 / 成分:Oral Corticosteroids、Oral antivirals、Hyperbaric Oxygen Therapy
登记的停止原因(原文):lack of enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-28
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
编号:NCT02923986登记状态:入组前撤回企业 / 申办者:Bio-Path Holdings, Inc.
药物 / 成分:BP1001 (varying dose)、BP1001 (fixed dose)、Dasatinib
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-28
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
编号:NCT03517995登记状态:入组前撤回企业 / 申办者:H. Lee Moffitt Cancer Center and Research Institute
药物 / 成分:Sulforaphane Administration、Placebo Administration、Standard of Care Surgery
登记的停止原因(原文):Grant not approved
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-28
Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis
编号:NCT03729310登记状态:入组前撤回企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Propel 'implant'、Triamcinolone、Nasopore
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-27
Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients
编号:NCT01263652登记状态:入组前撤回企业 / 申办者:Western Galilee Hospital-Nahariya
药物 / 成分:Diclofenac hydroxyethylpyrrolidine、orphenadrine、Tramadol、Dipyrone
登记的停止原因(原文):inability to complete recruitment as planned
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-27
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
编号:NCT04016116登记状态:入组前撤回企业 / 申办者:NYU Langone Health
药物 / 成分:Pembrolizumab、Ruxolitinib
登记的停止原因(原文):PI left the institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-05-27
ASC Therapy for Patients With Severe Respiratory COVID-19
编号:NCT04341610登记状态:入组前撤回企业 / 申办者:Copenhagen University Hospital, Rigshospitalet
药物 / 成分:Stem Cell Product
登记的停止原因(原文):Not approved by ethical committee
查看官方原始记录 ↗